HC Wainwright Reaffirms Buy Rating for Eyenovia (NASDAQ:EYEN)

HC Wainwright restated their buy rating on shares of Eyenovia (NASDAQ:EYENFree Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $12.00 target price on the stock.

Eyenovia Stock Performance

Shares of EYEN opened at $1.58 on Wednesday. The company has a 50-day moving average of $1.81 and a two-hundred day moving average of $1.66. The stock has a market cap of $69.71 million, a price-to-earnings ratio of -2.39 and a beta of 1.72. The company has a debt-to-equity ratio of 0.70, a current ratio of 4.05 and a quick ratio of 4.04. Eyenovia has a one year low of $1.05 and a one year high of $5.85.

Hedge Funds Weigh In On Eyenovia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in shares of Eyenovia in the third quarter worth $5,124,000. Financial Management Network Inc. acquired a new stake in Eyenovia during the 3rd quarter worth about $128,000. American International Group Inc. purchased a new position in Eyenovia during the 2nd quarter valued at about $32,000. Meitav Investment House Ltd. acquired a new position in shares of Eyenovia in the 2nd quarter valued at about $1,104,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Eyenovia in the second quarter worth approximately $53,000. 16.66% of the stock is currently owned by hedge funds and other institutional investors.

About Eyenovia

(Get Free Report)

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.

Featured Stories

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.